Third Rock Ventures V, L.P. bought RAPP
October 30, 2026 · Form 4 insider transaction
Third Rock Ventures V, L.P. bought 1,190,476 shares of Rapport Therapeutics, Inc. at $21.00 per share, a transaction worth $25.00M. The trade was recorded as grant or award and disclosed on an SEC Form 4, filed 4 days after the transaction.
Footnotes
Shares acquired in a private placement pursuant to a Securities Purchase Agreement dated October 28, 2026 by and between the Issuer, Third Rock Ventures V, L.P. ("TRV V") and Third Rock Ventures VI, L.P. ("TRV VI").; Each of Reporting Persons disclaims the existence of a Section 13(d) "group" as between any TRV V related parties and any TRV VI related parties and this report shall not be deemed an admission that any of such parties is or may be part of such a group with any of the other parties.; These shares are held directly by TRV VI. The general partner of TRV VI is Third Rock Ventures GP VI, L.P. ("TRV GP VI"). The general partner of TRV GP VI is TRV GP VI, LLC ("TRV GP VI LLC"). Each of TRV GP VI, and TRV GP VI LLC, disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares.